Navigation Links
La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level
Date:1/23/2012

the recipient of the Juvenile Diabetes Research Foundation's prestigious Scholar Award and in 2008 received the Outstanding Scientific Achievement Award from the American Diabetes Association.

The Center will focus on the development of type 1 diabetes immunotherapies, an area where Dr. von Herrath has specialized expertise. "My dream has always been to see the most promising immune-based interventions translated into better treatments for patients with diabetes," he said. "As head of the translational center, I will have an opportunity to pursue this dream, as well as forge new public-private collaborations to access other novel research ideas for potential development into better treatment options for people with type 1 diabetes."

Dr. Kronenberg said Novo Nordisk has the kind of strong biopharmaceutical development infrastructure that is necessary to take discoveries from research laboratories, into human clinical trials, and, if successful, into approved drugs. "By establishing this relationship with Novo Nordisk, Dr. von Herrath is accelerating an important and complementary process that is strongly supported by this Institute; one that moves discoveries toward becoming treatments available to patients," he said. "We are pleased that Dr. von Herrath has entered into this exciting endeavor, while at the same time maintaining his laboratory and research efforts at our Institute. Clearly, this type of arrangement is a win-win for the scientific community and for patients."

Based in Denmark, Novo Nordisk has a longstanding history in type 1 diabetes treatment and markets several drugs for diabetes sufferers worldwide. Globally, about 6,000 people work on the company's research and development activities.


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2

Related biology news :

1. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
2. La Jolla Institute discovers novel tumor suppressor
3. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
4. La Jolla Institute scientist leads team which discovers important new player in diabetes onset
5. La Jolla Institute scientist Klaus Ley receives Malpighi award
6. La Jolla Institute validates Type 1 diabetes computer models predictive success through lab testing
7. La Jolla Institute-led team illuminates cell pathway key to insulin resistance in Type 2 diabetes
8. La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders
9. La Jolla Institute opens major RNAi center for identifying genetic triggers of disease
10. La Jolla Institute discovers previously unknown cell interaction key in immune system attacks
11. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... discovery of genetic differences affecting up to a third ... prescribing the correct dose of 25 percent of drugs ... found two genetic variants that alter the activity level ... ranging from the painkiller codeine to the breast cancer ...
... Cullen College of Engineering has won a grant to make ... safer and more effective. The grant goes to Nuri ... National Science Foundation, it is valued at $330,000 for three ... an M.D./Ph.D a neurosurgeon with the University of Colorado School ...
... developed, none has matched the complexity of the fundamental ... of the cell,s activities would be possible without thin ... their functions. Understanding and controlling bilayers, properties ... an interdisciplinary team of Northwestern University researchers has determined ...
Cached Biology News:New genetic discovery could reduce the guesswork in drug dosing 2New genetic discovery could reduce the guesswork in drug dosing 3New genetic discovery could reduce the guesswork in drug dosing 4Parkinson's Surgery Research wins NSF Grant 2Study: Acidity can change cell membrane properties 2Study: Acidity can change cell membrane properties 3
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... 28, 2015 CD-adapco, the largest ... software, announced today it is joining the consortium ... provide state-of-the-art engineering simulation tools for analyzing particle ... and experiences in analyzing particle flow that will ... advance the understanding of flow modeling solutions. , ...
(Date:5/28/2015)... 28, 2015 Glenn Keet, CEO of ... Landscape of EMR/EHR Clinical Data Integration with EDC Systems ... in Washington, DC on June 14th-18th. , During the ... EMR/EHR systems with EDC, and will examine the value ... eSource and electronic health records/electronic medical records integration. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Global ... a point to ask his audiences if they ... trends including robotics, solar cells, fuel cells, rapid ... printers, advanced battery storage technology, driverless cars, artificial ... high-quality but inexpensive online education. , While ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... , , , ... VOLC ), a leader in the development, manufacturing and sales of ... disease, announced today its participation in the 2009 Transcatheter Cardiovascular Therapeutics ... for TCT includes a first look at new study data, live ...
... ROCKVILLE, Md., Sept. 21 Neuralstem, Inc. (NYSE Amex: ... (FDA) has approved its Investigational New Drug (IND) application to commence a ... disease) with its spinal cord stem cells. , , ... Neuralstem is the first company to commence a stem cell ...
... , NES-ZIONA, Israel, Sept. 21 PROLOR Biotech, ... the initiation of a Phase I clinical trial of its ... hGH-CTP is being developed to provide growth hormone ... multiple injections per week that are currently required with a ...
Cached Biology Technology:Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 2Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 3Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 5Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 6Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 4PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 2PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 3PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 4
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... for fully automated systems for a broad ... configured for applications ranging from compound logistics, ... loop screening, which means it has fully ... picking and follow up studies all at ...
... of experience in providing versatile liquid handling ... EVO platform delivers even more flexibility and ... Together with the new easy-to-use software, Freedom ... operate genomics, proteomics, and drug discovery applications. ...
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
Biology Products: